JP6642942B2 - セリン／トレオニンキナーゼ阻害剤 - Google Patents

セリン／トレオニンキナーゼ阻害剤 Download PDF

Info

Publication number
JP6642942B2
JP6642942B2 JP2016543584A JP2016543584A JP6642942B2 JP 6642942 B2 JP6642942 B2 JP 6642942B2 JP 2016543584 A JP2016543584 A JP 2016543584A JP 2016543584 A JP2016543584 A JP 2016543584A JP 6642942 B2 JP6642942 B2 JP 6642942B2
Authority
JP
Japan
Prior art keywords
methyl
pyridin
triazolo
pyrazol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016543584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502049A5 (OSRAM
JP2017502049A (ja
Inventor
ジェイムズ エフ． ブレイク，
ジェイムズ エフ． ブレイク，
アダム クック，
アダム クック，
ジョン ガウディーノ，
ジョン ガウディーノ，
インドラニ ダブリュー． グナワルダナ，
インドラニ ダブリュー． グナワルダナ，
エリック ジェイムズ ヒッケン，
エリック ジェイムズ ヒッケン，
ケビン ダブリュー． ハント，
ケビン ダブリュー． ハント，
マイケル ライオン，
マイケル ライオン，
アンドリュー ティー． メトカルフ，
アンドリュー ティー． メトカルフ，
ピーター ジェイ． モール，
ピーター ジェイ． モール，
デイビッド エー． モレノ，
デイビッド エー． モレノ，
ブラッド ニューハウス，
ブラッド ニューハウス，
リ レン，
リ レン，
ジェイコブ シュワルツ，
ジェイコブ シュワルツ，
フイフェン チェン，
フイフェン チェン，
ルイス ガッザード，
ルイス ガッザード，
ジェーン シュミット，
ジェーン シュミット，
スティーブ ドゥー，
スティーブ ドゥー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2017502049A publication Critical patent/JP2017502049A/ja
Publication of JP2017502049A5 publication Critical patent/JP2017502049A5/ja
Application granted granted Critical
Publication of JP6642942B2 publication Critical patent/JP6642942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016543584A 2013-12-30 2014-12-29 セリン／トレオニンキナーゼ阻害剤 Active JP6642942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361922042P 2013-12-30 2013-12-30
US61/922,042 2013-12-30
PCT/US2014/072555 WO2015103137A1 (en) 2013-12-30 2014-12-29 Serine/threonine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017502049A JP2017502049A (ja) 2017-01-19
JP2017502049A5 JP2017502049A5 (OSRAM) 2018-02-08
JP6642942B2 true JP6642942B2 (ja) 2020-02-12

Family

ID=52347479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016543584A Active JP6642942B2 (ja) 2013-12-30 2014-12-29 セリン／トレオニンキナーゼ阻害剤

Country Status (9)

Country Link
US (1) US9670208B2 (OSRAM)
EP (1) EP3089980B1 (OSRAM)
JP (1) JP6642942B2 (OSRAM)
KR (1) KR102396710B1 (OSRAM)
CN (1) CN105980387B (OSRAM)
BR (1) BR112016015236B1 (OSRAM)
CA (1) CA2934709C (OSRAM)
MX (1) MX375902B (OSRAM)
WO (1) WO2015103137A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013225737B2 (en) * 2012-03-01 2018-03-01 Array Biopharma Inc. Serine/threonine kinase inhibitors
MX2015004615A (es) 2012-10-16 2015-07-17 Hoffmann La Roche Inhibidores de serina/treonina cinasa.
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6449293B2 (ja) 2013-12-06 2019-01-09 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2015103133A1 (en) 2013-12-30 2015-07-09 Genentech, Inc. Serine/threonine kinase inhibitors
TN2018000020A1 (en) * 2015-07-20 2019-07-08 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors.
SI3374359T1 (sl) 2015-11-09 2020-04-30 Astrazeneca Ab Derivati dihidroimidazopirazinona uporabni pri zdravljenju raka
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN107383002B (zh) * 2016-05-17 2021-07-13 中国科学院上海药物研究所 一类含氟三氮唑并吡啶类化合物及其制备方法、药物组合物和用途
CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
JP2019522049A (ja) * 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
ES2969536T3 (es) * 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
EP3679159A1 (en) 2017-09-08 2020-07-15 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
US11937503B2 (en) * 2017-11-30 2024-03-19 Universal Display Corporation Organic electroluminescent materials and devices
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
TWI879771B (zh) 2019-06-06 2025-04-11 大陸商和記黃埔醫藥（上海）有限公司 三環類化合物及其用途
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN112159421A (zh) * 2020-10-10 2021-01-01 珠海奥博凯生物医药技术有限公司 一种2-氟-4-甲基-3-吡啶硼酸的制备方法
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
EP4326712A4 (en) * 2021-04-21 2025-03-05 The Regents of The University of California COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
PL366827A1 (en) 2001-06-21 2005-02-07 Smithkline Beecham Corporation Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
JP2009001551A (ja) 2007-05-18 2009-01-08 Sumitomo Chemical Co Ltd 有機硫黄化合物及びその有害節足動物防除用途
CA2828478C (en) * 2011-02-28 2019-12-31 Array Biopharma Inc. Serine/threonine kinase inhibitors
WO2013020062A1 (en) 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
AU2013225737B2 (en) 2012-03-01 2018-03-01 Array Biopharma Inc. Serine/threonine kinase inhibitors
BR112015004548A2 (pt) 2012-08-27 2017-08-08 Array Biopharma Inc inibidores de serina/treonina para tratamento de doenças hiperproliferativas
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
JP6449293B2 (ja) 2013-12-06 2019-01-09 ジェネンテック， インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
WO2015103133A1 (en) 2013-12-30 2015-07-09 Genentech, Inc. Serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
HK1225735A1 (zh) 2017-09-15
MX2016008624A (es) 2017-01-06
CA2934709C (en) 2022-08-30
BR112016015236A2 (pt) 2018-01-23
WO2015103137A1 (en) 2015-07-09
US20160304519A1 (en) 2016-10-20
KR102396710B1 (ko) 2022-05-10
CN105980387B (zh) 2019-04-19
BR112016015236A8 (pt) 2018-04-24
BR112016015236B1 (pt) 2023-11-14
EP3089980A1 (en) 2016-11-09
CA2934709A1 (en) 2015-07-09
CN105980387A (zh) 2016-09-28
JP2017502049A (ja) 2017-01-19
KR20160104036A (ko) 2016-09-02
US9670208B2 (en) 2017-06-06
EP3089980B1 (en) 2018-01-31
MX375902B (es) 2025-03-07

Similar Documents

Publication Publication Date Title
JP6642942B2 (ja) セリン／トレオニンキナーゼ阻害剤
CA2866086C (en) Serine/threonine kinase inhibitors
KR102379517B1 (ko) 세린/트레오닌 키나아제 억제제
AU2013225737A1 (en) Serine/threonine kinase inhibitors
EP4010334A1 (en) Heterocyclic wdr5 inhibitors as anti-cancer compounds
HK1230610A1 (en) Serine/threonine kinase inhibitors
HK1230610B (en) Serine/threonine kinase inhibitors
HK1225735B (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1254429B (en) Serine/threonine kinase inhibitors
HK1223877B (zh) 絲氨酸/蘇氨酸激酶抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180820

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200105

R150 Certificate of patent or registration of utility model

Ref document number: 6642942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250